Indications
Urinary tract infection
Ertapenem is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria:
Complicated intra-abdominal infections.
Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis.
... Read more
Ertapenem is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria:
Complicated intra-abdominal infections.
Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis.
Community-acquired pneumonia.
Complicated urinary tract infections including pyelonephritis.
Acute pelvic infections including postpartum endomyometritis,
septic abortion and post surgical gynecologic infections.
Ertapenem is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
Dosage And Administration
Ertapenem should be infused over 30 minutes in both the Treatment and Prophylactic regimens. Dosing considerations should be made in adults with advanced or end-stage renal impairment and those on hemodialysis.
Treatment regimen:
Adults and pediatric patients 13 years of age and older. The dosage should be 1 gram once a day intravenously or intramuscularly.
Patients 3 months to 12 years of age should be administered 15 mg/kg twice daily (not to exceed 1 g/day intravenously or intramuscularly.)
Intravenous infusion may be administered in adults and pediatrics for up to 14 days or intramuscular injection for up to 7 days.
Prophylaxis regimen for adults:
1 gram single dose given 1 hour prior to elective colorectal surgery.
Side Effects
Adults: The most common adverse reactions (≥5%) in patients treated with Ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. In the prophylaxis indication, the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.
Pediatrics: Adverse reactions in this population were comparable to adults. The most common adverse reactions (≥5%) in pediatric patients treated with Ertapenem, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain.
Precautions And Warnings
Serious hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams.
Seizures and other central nervous system adverse experiences have been reported during treatment.
Co-administration of Ertapenem with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures.
Clostridium deficits-associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs.
Caution should be taken when administering Ertapenem intramuscularly to avoid inadvertent injection into a blood vessel.
Pregnancy And Lactation
Pregnancy Category B. There are, however, no adequate and well-controlled trials in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Ertapenem is excreted in human breast milk. Caution should be exercised when Ertapenem is administered to a nursing woman. Ertapenem should be administered to nursing mothers only when the expected benefit outweighs the risk.